PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer.

[1]  T. Crocenzi,et al.  Randomized controlled trial of irinotecan drug‐eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver‐limited metastasis , 2015, Cancer.

[2]  B. Nordlinger,et al.  Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Lo,et al.  Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. , 2014, JAMA otolaryngology-- head & neck surgery.

[4]  Hartmut Link,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[5]  G. Poston,et al.  Enhanced recovery in the resection of colorectal liver metastases , 2014, Journal of surgical oncology.

[6]  G. Folprecht,et al.  Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. , 2014, European journal of cancer.

[7]  T. Hickish,et al.  Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. , 2014, The Lancet. Oncology.

[8]  R. Parks,et al.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.

[9]  G. Poston,et al.  Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI(®)) for colorectal liver metastases does not predict tumour destruction or long-term outcome. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  G. Poston,et al.  Perioperative chemotherapy for resectable colorectal liver metastases: where now? , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  P. Ghaneh,et al.  Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study , 2013, Cancer Chemotherapy and Pharmacology.

[12]  M. Choti,et al.  Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors , 2012, Clinical epidemiology.

[13]  T. Hernandez-Boussard,et al.  Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome , 2012, Annals of Surgical Oncology.

[14]  S. Curley,et al.  Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. , 2009, JAMA.

[15]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[16]  M. Choti,et al.  Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver Metastasis: An International Multi-Institutional Analysis of 1669 Patients , 2009, Annals of surgery.

[17]  L. Schwartz,et al.  Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Ellis,et al.  Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Lévi,et al.  Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Thomas Gruenberger,et al.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.

[21]  M. Berger,et al.  Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin , 2008, Clinical & Experimental Metastasis.

[22]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Rubbia‐Brandt,et al.  Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  T. Pawlik,et al.  Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Ben-Porat,et al.  Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. , 2005, Journal of the American College of Surgeons.

[26]  W. Hawkins,et al.  Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. , 2005, Journal of the American College of Surgeons.

[27]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[28]  L. Rubbia‐Brandt,et al.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  L. Ellis,et al.  Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy , 2003, Journal of Gastrointestinal Surgery.

[30]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[31]  T. Gruenberger,et al.  Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[32]  T. Eberlein.  Conversion to Resectability Using Hepatic Artery Infusion Plus Systemic Chemotherapy for the Treatment of Unresectable Liver Metastases From Colorectal Carcinoma , 2011 .

[33]  M. Roček,et al.  Hepatic Intra-Arterial Injection of Drug-Eluting Bead, Irinotecan (DEBIRI) in Unresectable Colorectal Liver Metastases Refractory to Systemic Chemotherapy: Results of Multi-Institutional Study , 2010, Annals of Surgical Oncology.